Apellis Pharmaceuticals, Inc.
APLS
Rank in Stocks
#3326
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical... Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-mediated disorders; APL-1030, a C3 inhibitor targeting multiple neurodegenerative diseases; and a novel combination therapy involving EMPAVELI with small interfering RNA (siRNA) to reduce hepatic C3 protein synthesis. Strategic alliances play a significant role, with a collaboration and licensing agreement in place with Swedish Orphan Biovitrum AB (publ) for the joint development of pegcetacoplan. The company also maintains a research partnership with Beam Therapeutics Inc., focusing on leveraging Beam's base editing technology to uncover new treatments for illnesses driven by complement system dysregulation. Established in 2009, Apellis Pharmaceuticals, Inc. operates from its headquarters in Waltham, Massachusetts.
Share Price
$41.03
Last synced: 2026-05-15
Market Cap
$5.25B
Change (1 day)
0.00%
Change (1 year)
51.57%
Country
US
Trade Apellis Pharmaceuticals, Inc. (APLS)
Category
Healthcare
P/E ratio for Apellis Pharmaceuticals, Inc. (APLS)
P/E ratio as of October 2026 TTM: 38.71
According to Apellis Pharmaceuticals, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 38.71. At the end of 2023 the company had a P/E ratio of -13.44.
P/E ratio history for Apellis Pharmaceuticals, Inc. from 2013 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 38.71 | -293.73% |
| 2024 | -19.98 | 48.68% |
| 2023 | -13.44 | 59.72% |
| 2022 | -8.41 | 57.33% |
| 2021 | -5.35 | -57.10% |
| 2020 | -12.47 | 102.70% |
| 2019 | -6.15 | 9.30% |
| 2018 | -5.63 | -61.35% |
| 2017 | -14.56 | 55.58% |
| 2016 | -9.36 | 71.49% |
| 2015 | -5.46 | -76.81% |
| 2014 | -23.53 | 44.99% |
| 2013 | -16.23 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -25.64% |
US
|
|
| -28.36 | -173.26% |
US
|
|
| -24.57 | -163.47% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -21.64% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.